Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
      QxMD      Google Scholar   
Citation:
Cancer Med vol 12 (7) 8211-7
Year:
2023
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
12
Parents:
3400  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Wyeth (HHSN261200800001E)  
Grants:
U10CA18082, U10CA180882, U10CA180791, U10CA180833, UG1CA233191, UG1CA233290, UG1CA233331, UG1CA233339, UG1CA189960, P30 CA008748  
Corr. Author:
 
Authors:
                               
Networks:
LAPS-MO011, LAPS-NY016, LAPS-OH007, NY018, PA121   
Study
CALGB-50303
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-580603
Phases:
3, 3
Keywords: